Skip to main content
Log in

Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Calcimimetic agents are small organic molecules that act as allosteric activators of the calcium sensing receptor (CaSR). In parathyroid cells, they lower the threshold for receptor activation by extracellular calcium ions and diminish parathyroid hormone (PTH) secretion. Calcimimetic compounds thus represent a novel way of controlling excess PTH secretion in clinical disorders such as secondary hyperparathyroidism (SHPT) due to chronic renal failure. Clinical trials have documented that the calcimimetic agent cinacalcet hydrochloride effectively lowers plasma PTH levels without increasing serum calcium or phosphorus concentrations in adult hemodialysis patients with SHPT. Serum phosphorus levels and values for the calcium-phosphorus ion product in serum often decline as plasma PTH levels fall during treatment. Experimental evidence suggests that calcimimetic agents may also impede the development of parathyroid gland hyperplasia, an integral component of SHPT due to chronic renal failure. Calcimimetic agents have considerable potential, therefore, as part of new therapeutic strategies for SHPT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Slatopolsky E, Delmez JA (1994) Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229–236

    CAS  PubMed  Google Scholar 

  2. Parfitt AM (1997) The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 52:3–9

    CAS  PubMed  Google Scholar 

  3. Mehls O, Wuhl E, Haffner D, Schaefer F, Tonshoff B (1996) Growth hormone treatment of short children with chronic renal failure before and after renal transplantation: rationale and recent results. Nephrol Dial Transplant 11:1747–1750

    CAS  PubMed  Google Scholar 

  4. Wuhl E, Haffner D, Nissel R, Schaefer F, Mehls O, and German Study Group for Growth Hormone Treatment in Chronic Renal Failure (1996) Short dialyzed children respond less to growth hormone than patients prior to dialysis. Pediatr Nephrol 10:294–298

    Article  CAS  PubMed  Google Scholar 

  5. Chesney RW, Moorthy AV, Eisman JA, Tax DK, Mazess RB, DeLuca HF (1978) Increased growth after long-term oral 1,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 298:238–242

    CAS  PubMed  Google Scholar 

  6. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during treatment with intermittent calcitriol and dialysis in children with chronic renal failure. Kidney Int 53:205–211

    CAS  PubMed  Google Scholar 

  7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483

    CAS  PubMed  Google Scholar 

  8. Dawson-Hughes B (1991) Calcium supplementation and bone loss: a review of controlled clinical trials. Am J Clin Nutr 54:274S–280S

    CAS  PubMed  Google Scholar 

  9. Brown EM, MacLeod RJ (2001) Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81:239–297

    CAS  PubMed  Google Scholar 

  10. Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J (2000) Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int 57:50–58

    Article  CAS  PubMed  Google Scholar 

  11. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977–2983

    CAS  PubMed  Google Scholar 

  12. Nemeth EF (1996) Calcium receptors as novel drug targets. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles in bone biology, 1st edn. Academic Press, San Diego, pp 1019–1035

  13. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040–4045

    CAS  PubMed  Google Scholar 

  14. Goodman WG (2001) Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187–1201

    Article  CAS  PubMed  Google Scholar 

  15. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607–617

    CAS  PubMed  Google Scholar 

  16. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942

    CAS  PubMed  Google Scholar 

  17. Brown EM (1993) Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens 2:541–551

    CAS  PubMed  Google Scholar 

  18. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296–1301

    CAS  PubMed  Google Scholar 

  19. Brown EM, Broadus AE, Brennan MF, Gardner DG, Marx SJ, Spiegel AM, Downs RW Jr, Attie M, Aurbach GD (1979) Direct comparison in vivo and in vitro of suppressibility of parathyroid function by calcium in primary hyperparathyroidism. J Clin Endocrinol Metab 48:604–610

    CAS  PubMed  Google Scholar 

  20. Ramirez JA, Goodman WG, Gornbein J, Menezes C, Moulton L, Segre GV, Salusky IB (1993) Direct in vivo comparison of calcium-regulated parathyroid hormone secretion in normal volunteers and patients with secondary hyperparathyroidism. J Clin Endocrinol Metab 76:1489–1494

    CAS  PubMed  Google Scholar 

  21. Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int 53:223–227

    Article  CAS  PubMed  Google Scholar 

  22. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58:436–445

    Article  CAS  PubMed  Google Scholar 

  23. Yamaguchi T, Chattopadhyay N, Kifor O, Ye C, Vassilev PM, Sanders JL, Brown EM (2001) Expression of extracellular calcium-sensing receptor in human osteoblastic MG-63 cell line. Am J Physiol Cell Physiol 280:C382–C393

    CAS  PubMed  Google Scholar 

  24. Yamaguchi T, Kifor O, Chattopadhyay N, Brown EM (1998) Expression of extracellular calcium (Ca2+o)-sensing receptor in the clonal osteoblast-like cell lines, UMR-106 and SAOS-2. Biochem Biophys Res Commun 243:753–757

    Article  CAS  PubMed  Google Scholar 

  25. Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, Barri YM, Cohen RM, Coburn JW (2002) The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017–1024

    CAS  PubMed  Google Scholar 

  26. Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, Blaisdell PW, Brenner RM, Turner SA, Martin KJ (2003) The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus product levels in hemodialysis patients with secondary hyperparathyroidism. Kidney Int 63:248–254

    Article  CAS  PubMed  Google Scholar 

  27. Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575–583

    CAS  PubMed  Google Scholar 

  28. Drüeke T, Cunningham J, Goodman WG, Horl WH, Braun J, Chen M-G, McCary LC, Steinhauslin-Jeanrenaud F, Turner SA, Ritz E (2001) Short-term treatment of secondary hyperparathyroidism with the calcimimetic agent AMG 073. J Am Soc Nephrol 12:764

    Google Scholar 

Download references

Acknowledgement

This work was supported in part by USPHS grants DK-60107 and DK-35423.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to William G. Goodman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goodman, W.G. Calcimimetic agents and secondary hyperparathyroidism: rationale for use and results from clinical trials. Pediatr Nephrol 18, 1206–1210 (2003). https://doi.org/10.1007/s00467-003-1290-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-003-1290-2

Keywords

Navigation